ArticleAmerican journal of cancer research2025
Comparative safety and efficacy of single-agent chemotherapy combined with microwave ablation versus radioactive seed brachytherapy in elderly patients with advanced NSCLC: a ten-year retrospective study.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elderly patients with advanced non-small cell lung cancer (NSCLC) often have limited tolerance for standard therapies and experience reduced efficacy with lower-intensity treatments. This study evaluated the safety and efficacy of single-agent chemotherapy combined with either microwave ablation (MWA) or radioactive iodine-125 seed ablation brachytherapy (RSABT) as first-line treatments, aiming to establish personalized, high-efficacy, and low-toxicity options for this vulnerable population. We conducted a retrospective analysis of 128 untreated elderly patients with advanced NSCLC from November 2013 to November 2023. 71 patients received RSABT plus chemotherapy, while 55 underwent MWA plus chemotherapy, with single-agent pemetrexed, docetaxel, or gemcitabine initiated 5-7 days post-procedure. Overall outcomes, including time to local progression (TTLP), overall survival (OS), and progression-free survival (PFS), did not differ significantly between the RSABT and MWA groups. However, in patients with tumors ≥ 4 cm, the RSABT group demonstrated significantly longer TTLP (14 versus 8 months,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.